Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03121352
Title Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Carboplatin + Nab-paclitaxel + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland Ohio 44106 United States Details
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland Ohio 44195 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field